T 1351/12 (Anti-CTLA-4 based immunotherapy/SQUIBB) of 16.7.2018

European Case Law Identifier:

ECLI:EP:BA:2018:T135112.20180716

Date of decision:

16 July 2018

Case number:

T 1351/12

Application number:

04785793.3

IPC class:

C07K 16/00
A61K 39/395
A61P 35/00

Language of proceedings:

Distribution:

Download and more information:

Decision text in EN (PDF, 322Â KB)
Documentation of the appeal procedure can be found in the Register
Bibliographic information is available in:	EN
Versions:	Unpublished

Title of application:

Surrogate therapeutic endpoint for anti-CTLA-4 based immunotherapy of disease

Applicant name:

E. R. Squibb & Sons, L.L.C.

Opponent name:

Board:

3.3.04

Headnote:

Relevant legal provisions:

European Patent Convention Art 83
European Patent Convention Art 111(1)
Rules of procedure of the Boards of Appeal Art 11

Keywords:

Main request - sufficiency of disclosure
Substantial procedural violation - (yes)
Remittal to the department of first instance (yes)
Reimbursement of appeal fee - (yes)

Catchwords:

Cited decisions:

Citing decisions:

Source: http://www.epo.org/law-practice/case-law-appeals/recent/t121351eu1.html

Date retrieved: 17 May 2021